Gilead Sciences (Nasdaq: GILD), a Foster Metropolis, CA-based biopharmaceutical firm, acquired CymaBay Therapeutics, Inc. (Nasdaq: CBAY), CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a Newark-based biopharmaceutical firm centered on progressive therapies for sufferers with liver and different persistent illnesses, for roughly $4.3 Billion in complete fairness worth.
With the acquisitions Gilead Sciences will broaden its choices. The addition of CymaBay’s investigational lead product candidate, seladelpar for the therapy of major biliary cholangitis (PBC) together with pruritus, enhances Gilead’s present liver portfolio and aligns with its dedication to bringing transformational medicines to sufferers.
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical firm centered on bettering the lives of individuals with liver and different persistent illnesses which have excessive unmet medical want. Seladelpar is a first-in-class investigational therapy for folks with PBC.
Led by CEO Daniel O’Day, Gilead Sciences is a biopharmaceutical firm that’s dedicated to advancing medicines to forestall and deal with life-threatening illnesses, together with HIV, viral hepatitis, COVID-19, and most cancers. It operates in additional than 35 nations worldwide.
Commenting on the information, Daniel O’Day stated: “I need to thank the CymaBay staff for his or her efforts and dedication to addressing this excessive unmet want. We sit up for advancing seladelpar and constructing on Gilead’s greater than 20-year legacy of treating and curing liver illness on a worldwide scale.”
FinSMEs
25/03/2024
